JP2023525753A5 - - Google Patents

Info

Publication number
JP2023525753A5
JP2023525753A5 JP2022567870A JP2022567870A JP2023525753A5 JP 2023525753 A5 JP2023525753 A5 JP 2023525753A5 JP 2022567870 A JP2022567870 A JP 2022567870A JP 2022567870 A JP2022567870 A JP 2022567870A JP 2023525753 A5 JP2023525753 A5 JP 2023525753A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
acid sequence
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525753A (ja
JP7894204B6 (ja
JP7894204B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031605 external-priority patent/WO2021226591A1/en
Publication of JP2023525753A publication Critical patent/JP2023525753A/ja
Publication of JP2023525753A5 publication Critical patent/JP2023525753A5/ja
Application granted granted Critical
Publication of JP7894204B2 publication Critical patent/JP7894204B2/ja
Publication of JP7894204B6 publication Critical patent/JP7894204B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567870A 2020-05-08 2021-05-10 Sirpアルファ、sirpベータ1およびsirpガンマ抗体、ならびにそれらの使用 Active JP7894204B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031605 WO2021226591A1 (en) 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2023525753A JP2023525753A (ja) 2023-06-19
JP2023525753A5 true JP2023525753A5 (cg-RX-API-DMAC7.html) 2024-05-22
JP7894204B2 JP7894204B2 (ja) 2026-07-23
JP7894204B6 JP7894204B6 (ja) 2026-08-20

Family

ID=

Similar Documents

Publication Publication Date Title
US10858444B2 (en) T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
JP6609724B1 (ja) 抗ヒト4−1bb抗体およびその使用
KR101862236B1 (ko) 항-cxcl13 항체 및 이의 이용 방법
WO2020088605A1 (zh) 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
JP2023525298A5 (cg-RX-API-DMAC7.html)
US20100278818A1 (en) Antibody specific for the Tn antigen for the treatment of cancer
GB2613464A (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
TW202011987A (zh) 螯合型放射核種之抗體
JP7843824B2 (ja) 抗体および使用方法
JP2024527288A (ja) 抗ccr8抗体及びその使用
KR20200053642A (ko) 치료 항체 및 그의 용도
TW202011988A (zh) 螯合型放射核種之抗體及清除劑
JP2022525400A (ja) フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインcar t細胞に対する拮抗薬としてのフルオレセインナトリウム
JP2008519028A (ja) B細胞悪性腫瘍の治療
JP2020508636A (ja) IFN−γ誘導性制御性T細胞転換性抗癌(IRTCA)抗体およびその使用
WO2024041651A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
US20250051440A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
CN114616245A (zh) 一种抗cd38的抗体及其用途
JP7855319B2 (ja) 抗cd26抗体と免疫チェックポイント阻害剤との併用療法
JP7384668B2 (ja) 細胞傷害性t細胞枯渇用組成物
HK40121520A (en) Anti-tnfr2 antibodies and methods of use thereof
JP2025084100A (ja) 抗tnfr2抗体およびその使用の方法
CN120603847A (zh) 抗il27r抗体及其使用方法
JP2025540215A (ja) Cd47遮断剤と抗bcma/抗cd3二重特異性抗体との組合せ療法